Search

Your search keyword '"Pals, Steven T."' showing total 38 results
Start Over Author "Pals, Steven T." Journal blood
38 results on '"Pals, Steven T."'

3. Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Author

De Groen, Ruben A.L., primary, De Groot, Fleur A, additional, De Haan, Lorraine M., additional, van Wezel, Tom, additional, Noordenbos, Troy, additional, Boehringer, Stefan, additional, Van Eijk, Ronald, additional, Raghoo, Richard, additional, Ruano, Dina, additional, Sijs-Szabo, Aniko, additional, te Boome, Liane, additional, Terpstra, Valeska, additional, Levenga, Henriette, additional, Nicolae, Aline, additional, Posthuma, Ward, additional, Focke-Snieders, Isabelle, additional, Hardi, Lizan, additional, den Hartog, Wietske, additional, Böhmer, Lara H., additional, Van Den Berg, Anke, additional, Mutseaers, Pim, additional, Van Der Poel, Marjolein W.M., additional, Abdul Hamid, Myrurgia, additional, Woei-a-Jin, F.J. Sherida H., additional, Janssens, Ann, additional, Tousseyn, Thomas, additional, Bovée, Judith, additional, Veelken, Hendrik, additional, Pals, Steven T, additional, Diepstra, Arjan, additional, Nijland, Marcel, additional, Kersten, Marie José, additional, Jansen, Patty M., additional, Cleven, Arjen, additional, and Vermaat, Joost S.P., additional

Published
2022
Full Text
View/download PDF

9. Immune evasion in primary testicular and central nervous system lymphomas: HLA loss rather than 9p24.1/PD-L1/PD-L2 alterations

Author

Minderman, Marthe, primary, Amir, Avital, additional, Kraan, Willem, additional, Schilder-Tol, Esther J. M., additional, Oud, Monique E. C. M., additional, Scheepstra, Cornelis G., additional, Noorduyn, Arnold L., additional, Kluin, Philip M., additional, Kersten, Marie José, additional, Spaargaren, Marcel, additional, and Pals, Steven T., additional

Published
2021
Full Text
View/download PDF

13. Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Author

Kersten, Marie José, primary, Minnema, Monique C., primary, Vos, Josephine M., primary, Nasserinejad, Kazem, primary, Kap, Marcel, primary, Kastritis, Eftathios, primary, Gavriatopoulou, Maria, primary, Chamuleau, Martine E.D., primary, Deeren, Dries, primary, Tick, Lidwine Winnifred, primary, Doorduijn, Jeanette K., primary, Offner, Fritz, primary, Bohmer, Lara H, primary, Amaador, Karima, primary, Liu, Roberto D, primary, Pals, Steven T, primary, and Dimopoulos, Meletios A., primary

Published
2019
Full Text
View/download PDF

14. High Frequencies of Mutated EZH2 and IRF8 and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype

Author

De Groen, Ruben A.L., primary, Van Eijk, Ronald, additional, van Wezel, Tom, additional, Raghoo, Richard, additional, Schrader, Anne-Roos, additional, Jansen, Patty M., additional, briaire-De Bruijn, Inge, additional, Kleiverda, Karin, additional, Vlasveld, Tom, additional, Terpstra, Valeska, additional, Levenga, Henriette, additional, Nicolae, Aline, additional, Posthuma, Ward, additional, Focke-Snieders, Isabelle, additional, Hardi, Lizan, additional, den Hartog, Wietske, additional, Van Den Berg, Anke, additional, Diepstra, Arjan, additional, Lugtenburg, Pieternella, additional, Kersten, Marie José, additional, Pals, Steven T, additional, Veelken, Hendrik, additional, Bovée, Judith, additional, Cleven, Arjen, additional, and Vermaat, Joost, additional

Published
2019
Full Text
View/download PDF

15. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma

Author

Schrader, Anne M.R., Jansen, Patty M., Willemze, Rein, Vermeer, Maarten H., Cleton-Jansen, Anne-Marie, Somers, Sebastiaan F., Veelken, Hendrik, van Eijk, Ronald, Kraan, Willem, Kersten, Marie José, van den Brand, Michiel, Stevens, Wendy B.C., de Jong, Daphne, Abdul Hamid, Myrurgia, Tanis, Bea C., Posthuma, Eduardus F.M., Nijland, Marcel, Diepstra, Arjan, Pals, Steven T., Cleven, Arjen H.G., and Vermaat, Joost S.P.

Published
2018
Full Text
View/download PDF

21. High prevalence of MYD88and CD79Bmutations in intravascular large B-cell lymphoma

Author

Schrader, Anne M.R., Jansen, Patty M., Willemze, Rein, Vermeer, Maarten H., Cleton-Jansen, Anne-Marie, Somers, Sebastiaan F., Veelken, Hendrik, van Eijk, Ronald, Kraan, Willem, Kersten, Marie José, van den Brand, Michiel, Stevens, Wendy B.C., de Jong, Daphne, Abdul Hamid, Myrurgia, Tanis, Bea C., Posthuma, Eduardus F.M., Nijland, Marcel, Diepstra, Arjan, Pals, Steven T., Cleven, Arjen H.G., and Vermaat, Joost S.P.

Published
2018
Full Text
View/download PDF

25. miRNA Profiling of B Cell Subsets: Specific miRNA Profile for Germinal Center B Cells with a Marked Variation Between Centroblast and Centrocytes.

Author

Tan, Lu Ping, primary, Wang, Miao, primary, Robertus, Jan-Lukas, primary, Schakel, Rikst Nynke, primary, Gibcus, Johan H, primary, Diepstra, Arjan, primary, Harms, Geert, primary, Peh, Suat Cheng, primary, Reijmers, Rogier M, primary, Pals, Steven T, primary, Visser, Lydia, primary, Kluin, Philip, primary, Poppema, Sibrand, primary, Kroesen, Bart-Jan, primary, and van den Berg, Anke, primary

Published
2008
Full Text
View/download PDF

26. miRNA Expression Profile of B-SLL Consistent with Normal Memory B Cells:BIC/miR–155 Specific Location in Proliferation Center.

Author

Wang, Miao, primary, Robertus, Jan-Lukas, primary, Tan, Lu-ping, primary, Harms, Geert, primary, Blokzijl, Tjasso, primary, Schakel, Rikst Niynke, primary, Kooistra, Klaas, primary, Rosati, Stefano, primary, Visser, Lydia, primary, Reijmers, Rogier M., primary, Pals, Steven T., primary, Kluin, P.M., primary, and van den Berg, Anke, primary

Published
2007
Full Text
View/download PDF

27. Specific Micro-RNA Expression Profile in Hodgkin Lymphoma.

Author

Ping Tan, Lu, primary, Harms, Geert, primary, Blokzijl, Tjasso, primary, Schakel, Rikst Nynke, primary, Gibcus, Johan, primary, Möller, Peter, primary, Küppers, Ralf, primary, Reijmers, Rogier M., primary, Pals, Steven T., primary, Poppema, Sibrand, primary, Kroesen, Bart-Jan, primary, and van den Berg, Anke, primary

Published
2007
Full Text
View/download PDF

28. Differences in the C13orf25 miRNA Cluster in Non-Hodgkin Lymphoma and Normal B-Cell Subtypes.

Author

Robertus, Jan-Lukas, primary, Wang, Miao, additional, Harms, Geert, additional, Blokzijl, Tjasso, additional, Schakel, Rikst Nynke, additional, de Jong, Daphne, additional, Reijmers, Rogier M., additional, Pals, Steven T., additional, Rosati, Stefano, additional, Schuuring, Ed, additional, Kluin, Philip M., additional, and van den Berg, Anke, additional

Published
2007
Full Text
View/download PDF

33. Egress of CD19+CD5+cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Author

Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F.M., Magadala, Padmaja, Steggerda, Susanne M., Huang, Min Mei, Kuil, Annemieke, Herman, Sarah E.M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., and Elias, Laurence

Abstract

Ibrutinib (PCI-32765) is a highly potent oral Bruton tyrosine kinase (BTK) inhibitor in clinical development for treating B-cell lymphoproliferative diseases. Patients with chronic lymphocytic leukemia (CLL) often show marked, transient increases of circulating CLL cells following ibrutinib treatments, as seen with other inhibitors of the B-cell receptor (BCR) pathway. In a phase 1 study of ibrutinib, we noted similar effects in patients with mantle cell lymphoma (MCL). Here, we characterize the patterns and phenotypes of cells mobilized among patients with MCL and further investigate the mechanism of this effect. Peripheral blood CD19+CD5+cells from MCL patients were found to have significant reduction in the expression of CXCR4, CD38, and Ki67 after 7 days of treatment. In addition, plasma chemokines such as CCL22, CCL4, and CXCL13 were reduced 40% to 60% after treatment. Mechanistically, ibrutinib inhibited BCR- and chemokine-mediated adhesion and chemotaxis of MCL cell lines and dose-dependently inhibited BCR, stromal cell, and CXCL12/CXCL13 stimulations of pBTK, pPLCγ2, pERK, or pAKT. Importantly, ibrutinib inhibited migration of MCL cells beneath stromal cells in coculture. We propose that BTK is essential for the homing of MCL cells into lymphoid tissues, and its inhibition results in an egress of malignant cells into peripheral blood. This trial was registered at www.clinicaltrials.govas #NCT00114738.

Published
2013
Full Text
View/download PDF

34. Memory CD4+CCR5+T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HIV-1

Author

Bunders, Madeleine J., van der Loos, Chris M., Klarenbeek, Paul L., van Hamme, John L., Boer, Kees, Wilde, Jim C.H., de Vries, Niek, van Lier, Rene A.W., Kootstra, Neeltje, Pals, Steven T., and Kuijpers, Taco W.

Abstract

Despite potential clinical importance, target cells for mother-to-child transmission of HIV-1 have not yet been identified. Cord blood–derived CD4+T cells are largely naive and do not express CCR5, the mandatory coreceptor for transmitted HIV-1 R5 strains in infants. In the present study, we demonstrate that in the human fetal and infant gut mucosa, there is already a large subset of mucosal memory CD4+CCR5+T cells with predominantly a Th1 and Th17 phenotype. Using next-generation sequencing of the TCRβ chain, clonally expanded T cells as a hallmark for memory development predominated in the gut mucosa (30%), whereas few were found in the lymph nodes (1%) and none in cord blood (0%). The gut mucosal fetal and infant CD4+T cells were highly susceptible to HIV-1 without any prestimulation; polproviral DNA levels were similar to infected phytohemagglutinin-stimulated adult PBMCs. In conclusion, in the present study, we show that extensive adaptive immunity is present before birth and the gut mucosa is the preferential site for memory CD4+T cells. These CD4+CCR5+T cells in the infant mucosa provide a large pool of susceptible cells for ingested HIV-1 at birth and during breastfeeding, indicating a mucosal route of mother-to-child transmission that can be targeted in prevention strategies.

Published
2012
Full Text
View/download PDF

35. Expression of Lymphocyte Homing Receptor as a Mechanism of Dissemination in Non-Hodgkin’s Lymphoma

Author

Pals, Steven T., Horst, Eveliene, Ossekoppele, Gert J., Figdor, Carl G., Scheper, R.J., and Meijer, Chris J.L.M.

Abstract

To investigate whether the lymphocyte homing receptor (LHR), an adhesion molecule believed to play an important role in the control of normal lymphocyte circulation, influences the spread of non-Hodgkin' x2018;s lymphoma (NHL), expression of LHR was examined in 107 NHL of various histologic and immunophenotypic subclasses. This analysis revealed that whereas NHL with a putative derivation from recirculating mature T and B lymphocytes almost invariably express high levels of LHR, those akin to sessile mature or immature lymphocytes tend to express lower levels of LHR. Furthermore, in a survey among diffuse large-cell lymphomas of the B-lineage, the tumors of 11 of 13 patients with stage III/IV disease expressed moderate to high levels of LHR, whereas only two of 17 patients with stage I/II disease had tumors that did so. These findings suggest that LHR is involved in the dissemination of NHL.

Published
1989
Full Text
View/download PDF

36. High Frequencies of Mutated EZH2and IRF8and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype

Author

De Groen, Ruben A.L., Van Eijk, Ronald, van Wezel, Tom, Raghoo, Richard, Schrader, Anne-Roos, Jansen, Patty M., briaire-De Bruijn, Inge, Kleiverda, Karin, Vlasveld, Tom, Terpstra, Valeska, Levenga, Henriette, Nicolae, Aline, Posthuma, Ward, Focke-Snieders, Isabelle, Hardi, Lizan, den Hartog, Wietske, Van Den Berg, Anke, Diepstra, Arjan, Lugtenburg, Pieternella, Kersten, Marie José, Pals, Steven T, Veelken, Hendrik, Bovée, Judith, Cleven, Arjen, and Vermaat, Joost

Abstract

Introduction

Published
2019
Full Text
View/download PDF

37. Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Author

Chang, Betty Y., Francesco, Michelle, De Rooij, Martin F. M., Magadala, Padmaja, Steggerda, Susanne M., Min Mei Huang, Kuil, Annemieke, Herman, Sarah E. M., Chang, Stella, Pals, Steven T., Wilson, Wyndham, Wiestner, Adrian, Spaargaren, Marcel, Buggy, Joseph J., and Elias, Laurence

Subjects
*PROTEIN-tyrosine kinases, *LYMPHOCYTIC leukemia, *LYMPHOPROLIFERATIVE disorders, *GENOTYPE-environment interaction, *CYTOKINES
Abstract

Ibrutinib (PCI-32765) is a highly potent oral Bruton tyrosine kinase (BTK) inhibitor in clinical development for treating B-cell lymphoproliferative diseases. Patients with chronic lymphocytic leukemia (CLL) often show marked, transient increases of circulating CLL cells following ibrutinib treatments, as seen with other inhibitors of the B-cell receptor (BCR) pathway. In a phase 1 study of ibrutinib, we noted similar effects in patients with mantle cell lymphoma (MCL). Here, we characterize the patterns and phenotypes of cells mobilized among patients with MCL and further investigate the mechanism of this effect. Peripheral blood CD19+ CD5+ cells from MCL patients were found to have significant reduction in the expression of CXCR4, CD38, and Ki67 after 7 days of treatment. In addition, plasma chemokines such as CCL22, CCL4, and CXCL13 were reduced 40% to 60% after treatment. Mechanistically, ibrutinib inhibited BCR- and chemokine-mediated adhesion and chemo-taxis of MCL cell lines and dose-dependently inhibited BCR, stromal cell, and CXCL12/ CXCL13 stimulations of pBTK, PPLCγ2, pERK, or pAKT. Importantly, ibrutinib inhibited migration of MCL cells beneath stromal cells in coculture. We propose that BTK is essential for the homing of MCL cells into lymphoid tissues, and its inhibition results in an egress of malignant cells into peripheral blood. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

38. Memory CD4+CCR5+ T cells are abundantly present in the gut of newborn infants to facilitate mother-to-child transmission of HTV- 1.

Author

Bunders, Madeleine J., van der Loos, Chris M., Klarenbeek, Paul L., van Hamme, John L., Boer, Kees, Wilde, Jim C. H., de Vries, Niek, van Lier, Rene A. W., Kootstra, Neeltje, Pals, Steven T., and Kuijpers, Taco W.

Subjects
*HIV infections, *CHILDREN of AIDS patients, *AIDS & children, *T cells, *INFANTS, *PHENOTYPES, *LYMPH nodes
Abstract

Despite potential clinical importance, target cells for mother-to-child transmission of HIV-1 have not yet been identified. Cord blood-derived CD4+ T cells are largely naive and do not express CCR5, the mandatory coreceptor for transmitted HIV-1 R5 strains in infants. In the present study, we demonstrate that In the human fetal and infant gut mucosa, there is already a large subset of mucosal memory CD4+CCR5+ T cells with predominantly a Th1 and Th17 phenotype. Using nextgeneration sequencing of the TCRβ chain, clonally expanded T cells as a hallmark for memory development predominated in the gut mucosa (30%), whereas few were found in the lymph nodes (1%) and none in cord blood (0%). The gut mucosal fetal and infant CD4+ T cells were highly susceptible to HIV-1 without any prestimulation; pol proviral DNA levels were similar to infected phytohemagglutininstimulated adult PBMCs. In conclusion, in the present study, we show that extensive adaptive immunity Is present before birth and the gut mucosa Is the preferential site for memory CD4+ T cells. These CD4+CCR5+ T cells In the infant mucosa provide a large pool of susceptible cells for Ingested HIV-1 at birth and during breastfeeding, Indicating a mucosal route of mother-to-child transmission that can be targeted in prevention strategies. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results